Osteopontin is a Prognostic Factor in Patients with Advanced Gastric Cancer

(E-pub Ahead of Print)

Author(s): Ozan Yazici*, Mutlu Dogan, Guze Ozal, Sedef Hande Aktas, Ahmet Demirkazik, Gungor Utkan, Filiz Cay Senler, Fikri Icli, Hakan Akbulut

Journal Name: Combinatorial Chemistry & High Throughput Screening
Accelerated Technologies for Biotechnology, Bioassays, Medicinal Chemistry and Natural Products Research

Become EABM
Become Reviewer
Call for Editor


Objective: Osteopontin (OPN), a phosphorylated sialoprotein, has been shown to overexpress in a variety of cancers and to contribute tumor progression and metastasis by increasing cell migration and adhesion. In the current study, we aimed to investigate the prognostic and predictive role of OPN in patients with advanced gastric cancer.

Methods: A total of 42 consecutive chemonaive patients with advanced gastric cancer and 29 healthy controls were included. The patients were treated with a modified DCF regimen. The blood samples were obtained before each chemotherapy cycle from the patients and once from the healthy controls. The plasma OPN measured by ELISA.

Results: The overall response and disease stabilization rates were 25% and 72%, respectively. The median serum OPN level of the patient group was significantly higher compared to healthy controls (176.9 ng/ml (range: 41.5 -521.4) vs 64.3 ng/ml (range 42.1-105.3 ng/ml), p<0.0001).The median overall survival time was 7.0 ± 1.1 (95% CI: 4.9–9.2) months and 1- year overall survival rate was %20.8. The patients who respond to mDCF had lower plasma OPN levels than the nonresponder ones (110.7±29.3 ng/mL, 211.9±24.4 ng/mL respectively, p=0.002). The performance status and the plasma OPN levels were found to be significant factors for overall survival in the multivariate analysis (p=0.004 and 0.016, respectively).

Conclusion: The serum OPN seems to be a novel significant prognostic and predictive factor in patients with advanced gastric cancer whom treated with DCF regimen.

Keywords: Gastric cancer, predictive factor, prognostic factor, Osteopontin, biomarker

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1386207323666200902135349
Price: $95

Article Metrics

PDF: 10